VOLITIONRX LTD - FORM 8-K/A - EX-10.02 - EXHIBIT 10.2 AMENDMENT TO PRIMARY LICENSE - January 11, 2012

Attached files

file filename
8-K/A - 8-K/A2 CURRENT REPORT - VOLITIONRX LTDf8ka2011012_8kz.htm
EX-10.10 - EXHIBIT 10.10 APPOINTMENT AS NON EXECUTIVE DIRECTOR - VOLITIONRX LTDf8ka2011012_ex10z10.htm
EX-10.01 - EXHIBIT 10.1 PATENT LICENSE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z01.htm
EX-10.13 - EXHIBIT 10.13 APPOINTMENT AS NON EXECUTIVE DIRECTOR - VOLITIONRX LTDf8ka2011012_ex10z13.htm
EX-10.12 - EXHIBIT 10.12 PATENT LICENCE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z12.htm
EX-10.03 - EXHIBIT 10.3 EXTENSION LETTER AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z03.htm
EX-10.06 - EXHIBIT 10.6 LICENSE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z06.htm
EX-10.11 - EXHIBIT 10.11 APPOINTMENT AS NON EXECUTIVE DIRECTOR - VOLITIONRX LTDf8ka2011012_ex10z11.htm
EX-10.14 - EXHIBIT 10.14 LICENSE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z14.htm
EX-10.05 - EXHIBIT 10.5 CONTRACT REPAYABLE GRANT ADVANCE - VOLITIONRX LTDf8ka2011012_ex10z05.htm
EX-10.07 - EXHIBIT 10.7 AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z07.htm
EX-10.08 - EXHIBIT 10.8 SHARE PURCHASE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z08.htm
EX-10.15 - EXHIBIT 10.15 SUPPLEMENTARY AGREEMENT TO THE SHARE PURCHASE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z15.htm
EX-10.04 - EXHIBIT 10.4 PRIMARY PATENT LICENSE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z04.htm
EX-10.09 - EXHIBIT 10.9 DEED OF NOVATION - VOLITIONRX LTDf8ka2011012_ex10z09.htm
EX-99.2 - EXHIBIT 99.2 VOLITION RX LIMITED PRO FORMA FINANCIAL STATEMENTS - VOLITIONRX LTDf8ka2011012_ex99z2.htm
EX-99.1 - EXHIBIT 99.1 SINGAPORE VOLITION PTE FINANCIAL STATEMENTS - VOLITIONRX LTDf8ka2011012_ex99z1.htm
EX-99.3 - EXHIBIT 99.3 UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS - VOLITIONRX LTDf8ka2011012_ex99z3.htm
EX-10.21 - EXHIBIT 10.21 FULL AND FINAL SETTLEMENT - VOLITIONRX LTDf8ka2011012_ex10z21.htm
EX-10.18 - EXHIBIT 10.18 CONSULTANCY AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z18.htm
EX-10.20 - EXHIBIT 10.20 SERVICE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z20.htm
EX-10.16 - EXHIBIT 10.16 DEED OF NOVATION - VOLITIONRX LTDf8ka2011012_ex10z16.htm
EX-10.19 - EXHIBIT 10.19 APPOINTMENT AS EXECUTIVE CHAIRMAN - VOLITIONRX LTDf8ka2011012_ex10z19.htm
EX-10.17 - EXHIBIT 10.17 PATENT LICENCE AGREEMENT - VOLITIONRX LTDf8ka2011012_ex10z17.htm
EX-3.1 - EXHIBIT 3.1 CERTIFICATE FOR RENEWAL AND REVIVAL OF CHARTER - VOLITIONRX LTDf8ka2011012_ex3z1.htm

Exhibit 10.2


THIS AMENDING AGREEMENT dated 31 July 2006 is between:


1.

IMPERIAL INNOVATIONS LIMITED (“Innovations”), a company incorporated in England and Wales whose principal place of business is at 12th Floor, Electrical Engineering Building; Imperial College, London SW7 2AZ; and


2.

CRONOS THERAPEUTICS LIMITED (“Licensee”), a company incorporated in England and Wales, whose principal place of business is at The London BioScience Innovation Centre, 2 Royal College Street, London NW1 OTU.


WHEREAS Innovations, and the Licensee have entered into a Patent License Agreement dated 19th


October 2005 (“Current Agreement”) for gene mapping technology and they now with to amend the


Current Agreement as appears below.


IT IS AGREED AS FOLLOWS:


1.

Status of this Agreement. This Amending Agreement is supplemental to the Current Agreement. Except as expressly amended by this Amending Agreement, the Current Agreement shall remain in full force and effect. Terms defined in the Current Agreement shall have the same meaning in this Amending Agreement, unless otherwise provided by this Amending Agreement.


2.

Extension. Innovations agrees to extend the Term of the Current Agreement as described in clause 9.2 of the Current Agreement.


3.

Commencement and Termination by Expiry. Clause 8.1 of the Current Agreement is amended by:


deleting the words “31st July 2006” and replacing them with the words “30 November 2006”.


4.

Commercialization


Further to the commercialization terms set out in clause 5 of the Current Agreement, the Licensee shall also keep Innovations regularly updated on a monthly basis on the status of the Licensee’s commercial progress.


5.

Termination


Notwithstanding clause 5.5 Imperial Innovations retains the right to terminate the license agreement on two weeks written notice prior to 30 November 2006.


AGREED by the Parties through their authorized signatories:


For and on behalf of

 

For and on behalf of

IMPERIAL INNOVATIONS LTD

 

CRONOS THERAPEUTICS LTD

 

 

 

 

 

 

/s/ Julian Smith

 

/s/ Satu Vainikka

Signed

 

Signed

 

 

 

Julian Smith

 

Satu Vainikka

Print name

 

Print name

 

 

 

C.F.O.O.

 

CEO

Title

 

Title

 

 

 

31st July, 2006

 

4/8/06

Date

 

Date




Stock widget

Investing forum

VOLITIONRX LTD Reports

Also read